Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and Pharmacokinetics of TQB3455 in Hematological Malignancies
NCT06550713Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2019
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TQB3455 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum tolerated dose at 48 weeks and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
TQB3455
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06550713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550713.